Roche Translational Neuroscience Symposium
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably.
In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.